# Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

> **NCT00005001** · PHASE2 · COMPLETED · sponsor: **Agouron Pharmaceuticals** · enrollment: 40 (—)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** HIV-1 Immunogen

## Key facts

- **NCT ID:** NCT00005001
- **Lead sponsor:** Agouron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005001, "Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00005001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*